WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced its financial results for the three- and six-month periods ended June 30, 2015. Highlights of and subsequent to the second quarter of 2015 include: The U.S. Food and Drug Administration (“FDA”) accepted for filing the New Drug Application (“NDA”) for Eagle’s bendamustine hydrochloride (HCl) rapid infusion product (the “rapid infusion” product) for the treatment of patients
| < Prev | Next > |
|---|
